Annual Congress Vienna 2009

Saturday, 12.09.2009
Sunday, 13.09.2009
Monday, 14.09.2009
Tuesday, 15.09.2009
Wednesday, 16.09.2009

Citations should be made in the following way: Authors. Title. Eur Respir J 2009; 34: Suppl. 53, abstract number.

Material from 2009:

4047 Abstracts
652 Slide presentations
300 Webcasts
93 Handouts
2150 e-posters
300 Multimedia files

Material from 2009: Show

Sustainability in treatment of COPD patients according to economics and quality of care

Oral Presentation
Chairs: F. Mihaltan (Bucharest, Romania), M. Roberts (Leytonstone, United Kingdom)

Download all media

Smoking-related disease events avoided quitting smoking – a simulated country perspective J. Dollerup, P. B. Poulsen, H. Keiding (Ballerup, Copenhagen, Denmark)
Smoking cessation compared to treatment of COPD and other smoking-related diseases using cost-effectiveness evidence J. Dollerup, P. B. Poulsen, H. J. Randskov, K. Møller Pedersen (Ballerup, Odense, Denmark)
Pharmacoeconomics of bronchial asthma in novouralsk of Sverdlovsk region E. Beltyukov, V. Naumova, M. Arkhipov (Ekaterinburg, Russian Federation)
Health promoting behaviors and health literacy in asthma D. Inal-Ince, S. Savci, H. Arikan, N. Vardar-Yagli, M. Bosnak-Guclu, M. Ozturk, G. Karakaya (Ankara, Turkey)
Efficacy of education programme in patients with chronic obstructive pulmonary disease assessed by the lung information needs questionnaire R. Wakabayashi, T. Ishii, T. Motegi, H. Kurosaki, N. Motohashi, K. Yamada, A. Gemma, R. Jones, K. Kida (Tokyo, Japan; Plymouth, United Kingdom)
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose E. Sims, L. Kemp, P. Dorinsky, D. Price (Norwich, United Kingdom; Horsham, United States Of America)
QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS D. Price, L. Kemp, P. Dorinsky, E. Sims (Norwich, London, United Kingdom)
Pharmaceutical cost of treatment in Greek COPD outpatients C. Dimitropoulos, T. Tsoutsouras, M. Ntaganou, I. Kostara, G. Alexias, I. Ntanos (Athens, Greece)